Trial participants will be required to go off their BPH medications for the duration of the trial (under the supervision of a doctor).
The Expander-2 clinical trial objective is to evaluate the safety and efficacy of the Urocross™ System and the procedure to treat patients with symptomatic BPH. The Expander-2 Trial is a blinded study, meaning that participants will not be told whether they are receiving the investigational treatment or not. Participants who do not receive the investigational treatment will be eligible to cross over to the investigational treatment group after the unblinding (after 3 months).
Trial participants will be required to attend follow-up appointments to evaluate their progress at 1 week* and 2 weeks, at 1-, 3-, and 6- months, as well as 1-, 2-, and 3- years post-treatment.
*1-week follow-up will be by telephone for pain assessment.
Watch an animation of the procedure
FIND OUT IF YOU MIGHT BE A CANDIDATE
Find out now if you might qualify to join the Expander-2 Trial and receive an investigational drug-free treatment at no cost. If it appears you might be qualified to join the trial, a patient education specialist will reach out to provide more information and further qualify you for the study.
CAUTION: the Urocross™ Expander System is for Investigational Use Only and is not for sale in the U.S. or outside the U.S.